EGFR and lung adenocarcinoma: Compared with systemic chemotherapy, EGFR-TKI targeted combined chemotherapy for stage-IV lung adenocarcinoma can increase the immune function of patients, more effectively inhibit the growth and proliferation of tumor cells, and reduce the level of oxidative stress.